犬の前立腺肥大症に対する酢酸オサテロンの治療効果

Abstract

The efficacy and clinical safety of osaterone acetate (TZV-906, Teikoku Hormone Mfg. Co. Ltd.), which displays anti-androgenic action, were assessed when used on dogs with benign prostatic hyperplasia. The subjects-17 dogs-were divided into 3 groups according to administered dosages of TZV-906: group L (n=2) dose if less than 0.25 mg/kg; group M (n=8) dose of 0.25 0.5mg/kg; and group H (n=7) dose of more than 0.5mg/kg. These doses were administered once daily for either 7 or 10 days. Efficacy was evaluated on the basis of clinical signs, radiograpy, digital palpation, and ultrasonography. After 8 days, prostatic size decreased in 15 out of 17 dogs (88.2%). Either excellent or good effects were observed in 13 out of the 17 dogs. These results indicate that a TZV-906 dose of 0.25-0.5mg/kg administered for 7 days is sufficient treatment for prostatic hyperplasia. The prostate-shrinking effect continued for 12 months. These findings show that continious oral doses of TZV-906 (0.25-0.5mg/kg) are easier than and equally as effective as chlomadinone-acetate implantation.